• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis.

作者信息

Li Lang, Gong Min, Bao Dingsu, Sun Jiachen, Xiang Zhou

机构信息

The Department of Orthopaedic Surgery, Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.; The Department of Orthopaedic Surgery, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, Sichuan, China.

The Department of Orthopaedic Surgery, Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.; Department of Orthopaedic Surgery, The Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

出版信息

Bone. 2020 May;134:115270. doi: 10.1016/j.bone.2020.115270.

DOI:10.1016/j.bone.2020.115270
PMID:32248981
Abstract
摘要

相似文献

1
Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis.地诺单抗和罗莫单抗不会增加原发性骨质疏松症患者发生心血管事件的风险：一项荟萃分析的再分析
Bone. 2020 May;134:115270. doi: 10.1016/j.bone.2020.115270.
2
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.地舒单抗或罗莫佐单抗治疗与原发性骨质疏松症患者心血管事件风险：系统评价和荟萃分析。
Bone. 2020 Jan;130:115121. doi: 10.1016/j.bone.2019.115121. Epub 2019 Oct 31.
3
Response to "Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis".对“地诺单抗和罗莫索单抗不会增加原发性骨质疏松症患者发生心血管事件的风险：一项荟萃分析的再分析”的回应
Bone. 2020 May;134:115271. doi: 10.1016/j.bone.2020.115271.
4
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.罗莫佐单抗治疗 1 年后序贯地舒单抗治疗 2 年可维持骨折风险降低：FRAME 扩展研究结果。
J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3.
5
Romosozumab Use and Cardiovascular Events.罗莫索单抗的使用与心血管事件
J Bone Miner Res. 2023 Mar;38(3):452-453. doi: 10.1002/jbmr.4695. Epub 2022 Sep 20.
6
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.罗莫佐单抗治疗 24 个月后序贯地舒单抗或安慰剂治疗 12 个月对骨密度低的绝经后妇女的影响：一项随机、双盲、2 期、平行组研究。
J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.
7
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.罗莫佐单抗的心血管结局和阿仑膦酸钠的保护作用。
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1343-1350. doi: 10.1161/ATVBAHA.119.312371. Epub 2019 May 23.
8
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.罗莫佐单抗治疗绝经后骨质疏松症妇女。
N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.
9
[Osteoporosis].[骨质疏松症]
Rev Med Suisse. 2015 Jan 14;11(456-457):108-13.
10
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.一项评价罗莫佐单抗治疗男性骨质疏松症的疗效和安全性的 III 期随机安慰剂对照试验。
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193. doi: 10.1210/jc.2017-02163.

引用本文的文献

1
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment.硬化素与心血管风险：评估罗莫佐单抗治疗骨质疏松症时的心血管安全性
Biomedicines. 2024 Dec 18;12(12):2880. doi: 10.3390/biomedicines12122880.
2
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease.抗硬化蛋白疗法在慢性肾脏病中的心血管安全性
Metabolites. 2021 Nov 10;11(11):770. doi: 10.3390/metabo11110770.